<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532854</url>
  </required_header>
  <id_info>
    <org_study_id>LG-EVCL001</org_study_id>
    <nct_id>NCT03532854</nct_id>
  </id_info>
  <brief_title>Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Drug-drug Interaction Between LGEV1801 and LGEV1802 in Healthy Korean Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug-drug interaction between LGEV1801 and
      LGEV1802 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCT,ss</measure>
    <time_frame>Day 1~Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Day 1~ Day 8</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe/Rosuvastatin -&gt; Valsartan -&gt; Valsartan and Ezetimibe/Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan -&gt; Valsartan and Ezetimibe/Rosuvastatin-&gt; Ezetimibe/Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan and Ezetimibe/Rosuvastatin -&gt; Ezetimibe/Rosuvastatin -&gt; Valsartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe/Rosuvastatin -&gt; Valsartan and Ezetimibe/Rosuvastatin-&gt; Valsartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan -&gt; Ezetimibe/Rosuvastatin -&gt; Valsartan and Ezetimibe/Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan and Ezetimibe/Rosuvastatin -&gt; Valsartan -&gt; Ezetimibe/Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan P.O</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe/Rosuvastatin</intervention_name>
    <description>Ezetimibe/Rosuvastatin P.O</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
    <other_name>Rosuzet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male

          -  Age between 19 and 50

          -  Subjects with BMI of 18~27 kg/m2 with a weight of 55kg or more

          -  Subjects with SBP of 90~150 mmHg and DBP of 60~150 mmHg

          -  Signed informed consent

        Exclusion Criteria:

          -  Presence of medical history or a concurrent disease

          -  Has a history of hypersensitivity to IP ingredients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LG chem</name>
      <address>
        <city>Seoul</city>
        <state>Gangseo-Gu</state>
        <zip>07795</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

